TerminatedNCT04742413
A 12-Month Observational Prospective Cohort Study to Analyze Cardiometabolic Profile Changes to Switch to Lurasidone in Patients With Schizophrenia. RESPECT Study.
Observational studyAges 18+Spain
Understand this study
Who could participate?
This study is for people with schizophrenia. Listed age limits: from 18 years. Other eligibility criteria apply.
- Listed locations
- Málaga and 9 more locationsSee all locations and recruitment
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: December 29, 2020
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 9
- Sponsor
- Angelini Farmacéutica
- Sponsor type
- Unknown or unclear
- Study type
- Observational
- Intervention type
- Interview / survey / observational
- Study phase
- Not clearly listed
- Locations
- Spain
- Age range
- Over 18 Years
- Official registry ID
- NCT04742413
- Official title
Show the full official title
A 12-Month Observational Prospective Cohort Study to Analyze Cardiometabolic Profile Changes to Switch to Lurasidone in Patients With Schizophrenia. RESPECT Study.
Recruitment & locations
TerminatedMálaga · Palma de Mallorca · León
5 more locations
- Salamanca
- Zamora
- Santiago de Compostela
- Vigo
- Madrid
A listed location does not confirm current availability.
Questions about this study
Who is behind this study?
The study sponsor is Angelini Farmacéutica.
Who can participate?
This study is for people with schizophrenia. Listed age limits: from 18 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as terminated.
